Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600K status confers therapeutic sensitivity to Cobimetinib, Vemurafenib in patients with Melanoma.
Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
This statement is based on a regulatory approval from the Health Canada:
COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.